home

Yasna farhoud darou co. active in synthesis of LVHV API and knowledge-based research activities in order to produce key intermediates and active components of specific pharmaceutical products and then produce their final product

Our Products

History of Research Activities Carried

Targeting more than fifteen molecules of active pharmaceutical ingredients

What Makes our Products different?

Manufacturing of the products from the most primitive form (sometimes from n-8). This keeps our manufacturing cost a lot lower than other very few competitors. Besides, the procurement of the raw material for production will be much easier as they are cheaper and more accessible.

The products manufactured under our method of synthesis are of higher purity comparing with many other rivals, especially the Chinese and Indian manufacturers.

According to the results of our tests, the anti cancer product of Farhoud Darou is of much higher quality in comparison with that of one the Chinese competitors.

We have registered a new XRD peak for one of our cardiovascular molecules for the first time in the world.

Very few pharmaceutical companies around the world have the science and know-how for manufacturing Orphan Drugs. However, we, at Farhoud Darou, have plenty of Orphan Drugs on our product list and in our pipeline.

Members of the Board

Dr Ali MOHAMMADI

Chairman & Shareholder

PhD Candidate of Organic Chemistry

Dr Ali RAMAZANI

Board Member & Shareholder

Full Professor of Organic Chemistry

Dr Hamideh AGHAHOSSEINI

Board Member & Shareholder

Post Doctorate of Organic Chemistry

Yasna farhoud darou co. active in synthesis of LVHV API and knowledge-based research activities in order to produce key intermediates and active components of specific pharmaceutical products and then produce their final product

Our Products

History of Research Activities Carried

Targeting more than fifteen molecules of active pharmaceutical ingredients

What Makes our Products different?

Manufacturing of the products from the most primitive form (sometimes from n-8). This keeps our manufacturing cost a lot lower than other very few competitors. Besides, the procurement of the raw material for production will be much easier as they are cheaper and more accessible.

The products manufactured under our method of synthesis are of higher purity comparing with many other rivals, especially the Chinese and Indian manufacturers.

According to the results of our tests, the anti cancer product of Farhoud Darou is of much higher quality in comparison with that of one the Chinese competitors.

We have registered a new XRD peak for one of our cardiovascular molecules for the first time in the world.

Very few pharmaceutical companies around the world have the science and know-how for manufacturing Orphan Drugs. However, we, at Farhoud Darou, have plenty of Orphan Drugs on our product list and in our pipeline.

Members of the Board

Dr Ali MOHAMMADI

Chairman & Shareholder

PhD Candidate of Organic Chemistry

Dr Ali RAMAZANI

Board Member & Shareholder

Full Professor of Organic Chemistry

Dr Hamideh AGHAHOSSEINI

Board Member & Shareholder

Post Doctorate of Organic Chemistry